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Abstract
Summary Current intake recommendations of 200 to
600 IU vitamin D per day may be insufficient for important
disease outcomes reduced by vitamin D.
Introduction This study assessed the benefit of higher-dose
and higher achieved 25-hydroxyvitamin D levels [25(OH)
D] versus any associated risk.
Methods and results Based on double-blind randomized
control trials (RCTs), eight for falls (n=2426) and 12 for
non-vertebral fractures (n=42,279), there was a significant
dose–response relationship between higher-dose and higher
achieved 25(OH)D and greater fall and fracture prevention.
Optimal benefits were observed at the highest dose tested to
date for 700 to 1000 IU vitamin D per day or mean 25(OH)D
between 75 and 110 nmol/l (30–44 ng/ml). Prospective
cohort data on cardiovascular health and colorectal cancer
prevention suggested increased benefits with the highest
categories of 25(OH)D evaluated (median between 75 and
110 nmol/l). In 25 RCTs, mean serum calcium levels were
not related to oral vitamin D up to 100,000 IU per day or
achieved 25(OH)D up to 643 nmol/l. Mean levels of 75 to
110 nmol/l were reached in most RCTs with 1,800 to
4,000 IU vitamin D per day without risk.
Conclusion Our analysis suggests that mean serum 25(OH)
D levels of about 75 to 110 nmol/l provide optimal benefits
for all investigated endpoints without increasing health
risks. These levels can be best obtained with oral doses in
the range of 1,800 to 4,000 IU vitamin D per day; further
work is needed, including subject and environment factors,
to better define the doses that will achieve optimal blood
levels in the large majority of the population.
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Introduction
Voluminous data suggest that higher 25-hydroxyvitamin D
[25(OH)D] serum concentrations are advantageous for
chronic disease prevention. At present, strong evidence
for causality is available for fracture [1] and fall endpoints
[2], while promising epidemiologic and mechanistic studies
suggest a key role of vitamin D in the preservation of
cardiovascular health [3–6] and the prevention of cancer[7]
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and other common chronic diseases [8]. However, benefits
of vitamin D on falls, fractures, cardiovascular health, and
cancer prevention that have been observed with higher 25
(OH)D levels cannot be achieved in the large majority of
individuals following current recommendations for vitamin
D intake. The current adequate intake (AI) for vitamin D, as
defined by the US Institute of Medicine (IOM), of 200 IU
per day for adults up to 50 years of age (5 µg), 400 IU per
day for adults between age 51 and 70 years (10 µg), and
600 IU per day for those aged 70 years and over (15 µg)
will achieve a serum 25(OH)D level of up to 50 or 60 nmol/
l for 2/3 of adults.
This review draws together recent work by the authors
and others on the benefits and risks of higher achieved 25
(OH)D levels beyond 60 nmol/l to provide guidance in
current efforts to define dose recommendations for vitamin
D in the absence of large randomized trials for non-skeletal
endpoints. We first examined double-blind randomized
control trial (RCT) data for fall and fracture prevention, as
well as mean serum calcium levels by dose and achieved 25
(OH)D levels. Specifically, we assessed a dose–response
relationship for these endpoints with established causality
to explore whether the benefit of higher vitamin D dose and
higher 25(OH)D levels is accompanied by an increase in
risk of hypercalcemia. Additionally, we assessed whether
there were single case reports of hypercalcemia or
nephrolithiasis from the same RCTs.
We also evaluated dose–response relationships for non-
skeletal outcomes of public health significance, including
cardiovascular disease and cancer, especially colorectal
cancer, in the context of case reports of hypercalcemia
and documented 25(OH)D levels. Our overarching goal
was to determine the optimal 25(OH)D level and vitamin D
intake that correspond to optimal health without risk of
adverse effects.
Methods
In this review, we summarize evidence for optimal serum
25(OH)D levels with respect to benefit and risk. The
established benefits of higher vitamin D dose and higher
achieved serum 25(OH)D levels were reduction in falls and
fractures as summarized in two 2009 meta-analyses of
double-blind RCTs [1, 2]. The established risk of higher
intake of vitamin D or higher achieved serum 25(OH)D
level that we evaluated in the same RCTs and any available
RCTs of vitamin D supplementation and reported 25(OH)D
status was hypercalcemia, evaluated as mean serum calcium
level. We also examined case reports of hypercalcemia or
nephrolithiasis in these trials.
Additionally, we review benefits of vitamin D with the
strongest evidence today from prospective epidemiological
studies that are supported by strong mechanistic evidence,
specifically reduction of cardiovascular disease (incident
hypertension and cardiovascular mortality) and colorectal
cancer. Weaker evidence of a beneficial effect of vitamin D
exists for other diseases, including multiple sclerosis [9],
tuberculosis [10], insulin resistance [11, 12], other cancers
[13–16], osteoarthritis [17, 18], and prevalent hypertension
[19–21], but these are not considered here. For the
assessment of risk in observational studies, we include data
on serum calcium levels with any reported 25(OH)D level
from case reports of vitamin D intoxication.
The risk assessment method used is a slight modification
of the Institute of Medicine’s tolerable upper intake level
(UL) method, as applied in a previous risk assessment on
vitamin D by some of the current authors [22]. Our
procedure uses the UL protocol exactly, except for a
conservative selection of data so that no further correction
for uncertainty is required [23]. Details of the entire
literature up to that time were described in the previous
risk assessment [22].
The benefit and risk that occur with increases in 25(OH)
D concentration were placed in context with each other
graphically using trend-plots for each selected endpoint
(decreased risk of falls and non-vertebral fractures) at
different doses of vitamin D and achieved 25(OH)D levels.
Given the limitations of using mean achieved serum
calcium levels reported as a risk endpoint in trials of
vitamin D supplementation, we also used individual serum
calcium values in published case reports of hypercalcemia
alleging vitamin D intoxication to compare with the
prospective cohort data relating 25(OH)D concentrations
to risks of cardiovascular disease and colorectal cancer.
Results
Benefit and risk data from RCTs
Benefit of higher 25(OH)D levels on non-vertebral fracture
prevention
In a recent meta-analysis, the efficacy of oral supplemental
vitamin D in preventing non-vertebral and hip fractures
among older individuals was examined (age 65+years) [1].
The analysis included 12 double-blind RCTs for non-
vertebral fractures (n=42,279; [1, 2, 24–32]) and eight
RCTs for hip fractures (n=40,886; [24, 25, 29, 30, 32–35])
comparing oral vitamin D with or without calcium with
calcium or placebo. The pooled relative risk (RR) was 0.86
(95% CI, 0.77–0.96) for prevention of non-vertebral
fractures and 0.91 (95% CI, 0.78–1.05) for the prevention
of hip fractures but with significant heterogeneity for
both endpoints. Including all trials, anti-fracture efficacy
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increased significantly with higher-dose and higher
achieved blood 25(OH)D levels for any non-vertebral
fractures and hip fractures separately. Consistently pooling
trials with a higher received dose of more than 400 IU per
day (received dose of 482–770 IU per day) resolved
heterogeneity and resulted in fracture reduction, while the
lower received dose (340–380 IU per day) did not reduce
fracture risk. For the higher doses, the pooled RR was 0.80
(95% CI, 0.72–0.89; n=33,265 persons from nine trials) for
non-vertebral fractures and 0.82 (95% CI, 0.69–0.97; n=
31,872 from five trials) for hip fractures. The higher doses
reduced non-vertebral fractures significantly in community-
dwelling (−29%) and institutionalized older individuals
(−15%), and its effects were independent of additional
calcium supplementation. Non-vertebral fracture prevention
started with achieved 25(OH)D levels of at least 75 nmol/
l in the treatment group. From left to right, Fig. 1a indicates
increased anti-fracture efficacy with higher dose and
Fig. 1b with higher achieved 25(OH)D levels in the
treatment group [meta-regression analyses by dose, p=
0.003; by achieved 25(OH)D level, p=0.04; these values
are based on 12 trials for dose and ten trials with measured
25(OH)D levels]. From Fig. 1a optimal fracture prevention
occurred in trials with achieved mean 25(OH)D levels of
approximately 75 to 110 nmol/l.
This threshold of optimal non-vertebral fracture pre-
vention is supported by a large cross-sectional and
population-based study that showed a positive dose–
response association between higher 25(OH)D levels and
hip bone density both in younger and older adults [36]. In
the regression plots, higher serum 25(OH)D levels were
associated with higher hip bone density throughout the
reference range of 22.5 to 94 nmol/l in all subgroups by
age and ethnicity. In younger whites and younger Mexican
Americans, higher 25(OH)D levels were associated with
higher hip bone density even beyond 100 nmol/l.
Benefit of higher 25(OH)D levels on fall prevention
In another meta-analysis, the efficacy of oral supplemental
vitamin D in preventing falls among older individuals (age
65+years) was examined [2]. Only double-blind RCTs with
prospective fall assessment were considered (falls were
assessed as a primary or secondary endpoint, authors stated
how falls were defined and assessed, and falls were
assessed over the whole trial period). The analysis included
eight double-blind RCTs (n=2426; [31, 37–43]) comparing
oral vitamin D with or without calcium with calcium or
placebo. The pooled RR was 0.87 (95% CI, 0.77–0.99) for
prevention of falls but with significant heterogeneity (Q-
test, p=0.05). Heterogeneity was observed for dose of
vitamin D (low-dose, <700 IU per day versus higher-dose,
700 to 1000 IU per day; p=0.02) and achieved 25(OH)D
level (<60 nmol/l versus≥60 nmol/l; p=0.005). Higher-
dose supplemental vitamin D reduced fall risk by 19%
(pooled RR=0.81; 95% CI, 0.71–0.92; n=1921 from seven
trials). Falls were not reduced by low-dose supplemental
vitamin D (pooled RR=1.10, 95% CI, 0.89–1.35 from two
trials) or by achieved serum 25(OH)D concentrations less
than 60 nmol/l (pooled RR=1.35, 95% CI, 0.98–1.84). Fall
prevention increased with higher dose (Fig. 2a) and with
higher achieved 25(OH)D levels in the treatment group
(Fig. 2b). Similar to non-vertebral fracture prevention
described above, optimal fall prevention appeared to occur
in trials with achieved mean 25(OH)D levels of approxi-
mately 75 to 100 nmol/l (see Fig. 2b).
This threshold of optimal fall prevention is supported by a
large cross-sectional and population-based study that showed
a dose–response association between higher 25(OH)D levels
and better lower extremity function in older adults [44]. For
both tests (8-foot walk, repeated sit-to-stand), performance
speed continued to increase throughout the reference range of
25(OH)D (22.5 to 94 nmol/l) with most of the improvement
occurring in 25(OH)D levels going from 22.5 to approxi-
mately 60 nmol/l. Further improvement was seen in the range
of 60–94 nmol, but the magnitude was less dramatic.
Levels of 25(OH)D in relation to change in mean serum
calcium levels and hypercalcemia in controlled trials
We included the published 22 RCTs involving an oral dose
(either D2 or D3) of greater than or equal to 1,800 IU per
day (or the equivalent in weekly, monthly, bolus doses,
etc…) and in which both mean serum calcium and serum
25(OH)D were reported [45–66]. The reason for this cutoff
stems from the purpose of conducting a risk assessment for
doses close to or greater than the IOM identification of
2,000 IU as the tolerable UL. In addition, in Fig. 1a, b, we
plotted mean serum calcium levels from five double-blind
RCTs that reported serum calcium levels after vitamin D
supplementation along with the fall and fracture endpoints
[29, 34, 38, 43, 67]. The vitamin D doses in these five trials
ranged from 400 to 800 IU vitamin D per day. In Fig. 1a, b,
a total of 28 data points for mean calcium levels are
depicted (two data points stem from one trial for the report
by type of dwelling [45]). In Fig. 1a, b, we drew a trend
line based on this series of mean serum calcium levels. The
horizontal trend line indicates that mean serum calcium
levels did not increase with higher doses of vitamin D up to
100,000 IU per day (Fig. 1a) or with higher achieved 25
(OH)D levels up to 643 nmol/l (Fig. 1b). The one trial with
100,000 IU dose of vitamin D per day had a very short
duration of 4 days, while the other trials ran for at least one
half-life of vitamin D, which is 3 to 6 weeks. We address
treatment duration in more detail later in the Results
section. Notably, in none of the trials was there a shift of
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mean serum calcium levels above the normal physiologic
range (>2.6 mmol/l) with vitamin D treatment. However, in
the Honkanen et al. trial depicted in Fig. 1a, b, there was an
increase in mean serum calcium levels above 2.6 nmol/l in
the institutionalized control group receiving calcium sup-
plementation without vitamin D [45]. Not shown in Fig. 1
is one controlled trial with a report of increased mean
calcium levels above 2.6 nmol/l as the trial did not measure
25(OH)D levels: the Narang et al. 1984 trial randomized 30
healthy adults to 0, 400, 800, 1,200, 2,400, and 3,800 IU
per day for 90 days and observed a significant increase in
mean serum calcium levels in the two highest dose groups
(2.62 and 2.82 mmol/l, respectively) [68]. The limitations
of the Narang study include the location and population
studied (India), the small sample size (n=5 per group), and
failure to measure serum 25(OH)D levels. Finally, the
finding of a significant increase in mean serum calcium
levels at these doses has not been replicated in any
subsequent published RCT.
For reports of single cases of hypercalcemia, two RCTs
of the 28 RCTs identified and depicted in Fig. 1a, b
reported single cases where serum calcium levels rose
above the normal range (>2.6 mmol/l): (1) Talwar et al.
2007 with a daily dose of 2,000 IU plus 1,500 mg calcium
supplementation in healthy black women treated for
12 months [48]; and (2) Maalouf et al. 2008 with a daily
dose of 2,000 IU vitamin D in healthy Lebanese adoles-
cents treated for 12 months [47]. In the Talwar study, six
isolated incidents of mild hypercalcemia occurred in eight
clinical visits over 3 years in 208 women. The authors
report that all six cases of hypercalcemia resolved on the
repeat fasting sample. In the Maalouf study, hypercalcemia
ranging from 2.7 to 2.77 nmol/l was described in seven of
340 adolescents, five cases in the placebo group, one with
1,400 IU vitamin D per week (equivalent to 400 IU per
day), and one with 14,000 IU vitamin D per week
(equivalent to 2,000 IU per day).
Of all controlled trials with vitamin D, an increased
incidence of nephrolithiasis occurred only in the very large
Women’s Health Initiative (WHI) trial (involving 400 IU
vitamin D plus 1,000 mg of calcium per day) [24].
We also identified ten uncontrolled trials with oral
vitamin D supplementation at doses of at least 1,800 IU
per day and reported serum calcium levels after treatment
[69–77]. Of these, two reported an increase in mean serum
calcium levels above the normal range or single cases with
hypercalcemia: (1) Tucci et al. reported a mean serum
calcium level that exceeded 2.6 mmol/l at baseline and after
administration of 7,120 IU vitamin D per day in adult
primary hyperparathyroidism patients [74]. Mean serum
calcium levels were 2.73 mmol/l at baseline and after
treatment; however, the authors also reported of two
patients in whom serum calcium levels rose from 2.8 to
3.03 mmol/l and from 2.83 to 3.05 mmol/l, respectively. (2)
Restorff et al. reported of two single cases of mild
hypercalcemia (2.69 mmol/l) at 3 months and normal levels
at 6 months in one small uncontrolled trial of 33 elderly
rheumatology patients with severe vitamin D deficiency
treated with a single oral dose of 300,000 IU vitamin D3
[76].
The other remaining clinical trials we identified (both
controlled and uncontrolled) did not assess serum calcium
and/or serum 25(OH)D [30, 78–81]. In some instances, serum
calcium was assessed, but only the observation of a lack of
hypercalcemia or no significant change in serum calcium was
reported [82–89]. Vitamin D daily (or equivalent) oral doses
ranged in these trials from 2,000–300,000 IU.
Benefit and risk data from observational data
Data from epidemiologic studies on the RR of incident
hypertension [4], all-cause [90], cardiovascular [90] mor-
tality, and colorectal cancer [91] based on categories of
median 25-hydroxyvitamin D levels are presented in Fig. 2.
For all-cause and cardiovascular mortality, we included a
population-based prospective cohort study (National Health
and Nutrition Survey III) controlling for age, sex, race/
ethnicity, season of blood-draw, income, region, body mass
Fig. 1 Evidence from controlled RCTs. Trend-plots on benefit (fall
and non-vertebral fracture prevention) and risk (mean achieved serum
calcium levels) by dose of vitamin D and achieved 25(OH)D levels. a
By dose of vitamin D. b By achieved 25(OH)D level. Black circles
represent relative risks (RRs) from 12 double-blind RCTs on vitamin
D supplementation and non-vertebral fracture risk as summarized in a
2009 meta-analysis (Bischoff-Ferrari et al.; Archives of Internal
Medicine 2009 [1]). Trend line is based on series of effect sizes
(circles). For any non-vertebral fractures, anti-fracture efficacy
increased significantly with higher received dose [meta-regression:
Beta=−0.0007; p=0.003; (a)] and higher achieved 25-hydroxyvitamin
D levels [meta-regression: Beta=−0.005; p=0.04; (b)]. Black triangles
represent relative risks (RRs from eight double-blind RCTs on vitamin
D supplementation and fall risk as summarized in a 2009 meta-
analysis (Bischoff-Ferrari et al.; in press British Medical Journal [2]).
Trend line is based on series of effect sizes (triangles). A meta-
regression, which included 2,426 individuals from eight RCTs,
indicated a significant inverse relationship between higher treatment
dose and the risk of sustaining at least one fall [Beta-estimate for dose,
700 IU or higher compared with less=−0.337; p=0.02; (a)]. A meta-
regression, which included 1,447 individuals from six RCTs with
reported 25(OH)D levels, indicated a significant inverse relationship
between higher achieved 25(OH)D level in the treatment group and
the risk of sustaining at least one fall [Beta-estimate for a 25(OH)D of
60 nmol/l or higher compared with lower=−0.586; p=0.005; (b)].
Gray squares represent mean calcium levels in the treatment group
from 25 vitamin D supplementation trials (28 data points; one trial
with separate report from community-dwelling and hospitalized older
individuals [45]). Trend line is based on series of mean serum calcium
levels (gray squares). The doses of vitamin D applied in these trials
ranged from 400 to 100,000 IU vitamin D per day. There was flat
trend line for mean serum calcium levels with higher dose of vitamin
D (Fig. 1a) and higher achieved 25-hydroxyvitamin D levels (Fig. 1b)
b
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index, physical activity, smoking status, cigarette pack
years, asthma, chronic obstructive pulmonary disease, and
renal function in community-dwelling individuals age
65 years and older [90]. Consistent findings have been
reported from a large cohort of patients undergoing
angiography [3] and a second report within the National
Health and Nutrition Survey III including younger individ-
uals age 20 years and older [92], which confirmed an
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optimal 25(OH)D range of 100 to 120 nmol/l for all-cause
mortality.
For colorectal cancer, we included a quantitative meta-
analysis of five studies [91]. For all non-skeletal endpoints
of public health significance illustrated in Fig. 2, there was
a dose–response of better health status with higher median
25(OH)D levels. By visual inspection, the desirable median
serum 25(OH)D level to be achieved for all non-skeletal
endpoints included in this report was approximately
100 nmol/l.
The solid gray diamonds in Fig. 2 relate to 24 case
reports of hypercalcemia allegedly from vitamin D intox-
ication with corresponding 25(OH)D levels [93–115]. Only
two out of 24 cases with hypercalcemia were reported at 25
(OH)D levels below 240 nmol/l 25(OH)D [93, 110], one of
which involved an 85-year-old woman who reported
consuming 400 IU/d vitamin D and had a 25(OH)D of
62 nmol/l [93], the other in a newly arrived international
10-month-old adoptee [110]. These appear to be aberrant
cases which have not been replicated in the literature.
Extending to a cutoff of 400 nmol/l 25(OH)D, a third
case with hypercalcemia occurred with 25(OH)D levels
of 250 nmol/l. The third case occurred in a 77-year-old
woman with primary hyperparathyroidism who received
50,000 IU D2 daily instead of weekly for 2 years with a
25(OH)D level of 250 nmol/l [96]. All other cases of
hypercalcemia (n=21) were reported at 25(OH)D levels of
525 to 2070 nmol/l, clearly outside a target range of 75 to
110 nmol/l for optimal health illustrated in Figs. 1b and 2.
There are also case reports in the published literature
describing individual circumstances where extremely high
vitamin D doses have been claimed (ranging from
50,000 IU to 150,000 IU per day vitamin D2 or D3),
verified by correspondingly high serum 25(OH)D values
(ranging from 107 to 1126 nmol/l), but serum calcium
levels were reported to not exceed the threshold for
hypercalcemia (2.6 mmol/l) [116] [98, 117].
Summary of serum 25(OH)D response to oral vitamin D
In summary, the data for fall and fracture prevention as well
as epidemiologic data on preservation of cardiovascular
health, general mortality and colorectal cancer prevention
suggest that serum 25(OH)D levels close to 100 nmol/l are
desirable and carry no risk of hypercalcemia, as evidenced
by controlled trials. Figure 3 illustrates 25(OH)D response
Fig. 2 Trend-plots on benefit from observational studies (cardiovascular
disease prevention and colorectal cancer prevention) and risk (case
reports of hypercalcemia) by achieved 25(OH)D level. Dashed lines
relate to data from epidemiologic studies on the RR of incident
hypertension [4], all-cause [90], cardiovascular [90], mortality, and
colorectal cancer [91] based on categories of median 25-hydroxyvitamin
D levels. For colorectal cancer, we included a quantitative meta-analysis
of five studies [91]. Based on this summary of non-skeletal endpoints of
public health significance, there was a dose–response of better health
status with higher median 25(OH)D levels. By visual inspection, the
desirable median serum 25(OH)D level to be achieved for all endpoints
was approximately 100 nmol/l. The solid gray diamonds relate to 24
case reports of hypercalcemia with corresponding 25(OH)D levels.
Twenty-two of 24 cases of hypercalcemia were reported at 25(OH)D
levels beyond 240 nmol/l 25(OH)D
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to vitamin D doses between 200 to 1,000 IU per day in fall
and fracture trials and 1,800 IU to 7,600 IU from other
RCTs included in Fig. 1a, b. With a supplement equal to the
AI for young adults of 400 IU per day, data from three large
RCTs achieved a mean increase in 25(OH)D levels to
56.7 nmol/l (range, 44 to 64 nmol/l) after a mean treatment
duration of 653 days leaving more than 50% of individuals
below the desirable target range of at least 75 nmol/l for fall
and fracture reduction and with very limited chances to
reach an optimal range close to 100 nmol/l. With a
supplement of 800 IU vitamin D per day, a recommenda-
tion 200 IU higher than the highest of the AI values for the
oldest segment of the population, tested in nine RCTs for a
mean duration of 697 days resulted in a mean increase in
25(OH)D levels to 75 nmol/l (range, 60 to 105 nmol/l) after a
mean treatment duration of 697 days (range, 56 to 1,680 days)
leaving about 50% of individuals below the desirable target
range of at least 75 nmol/l for fall and fracture reduction and a
small chance to reach an optimal range close to 100 nmol/l.
Most healthy younger and older adults reached the target range
of 75 to 110 nmol/l with 1,800 IU to 4,000 IU vitamin D3 per
day treated for at least 42 days.
Discussion
Recommendations for consumption of a nutrient are a
function of the tolerable UL and the recommended dietary
allowances (RDA) or for some nutrients the AI. For vitamin
D, the necessary evidentiary basis for a RDA (i.e., the mean
requirement and an estimate of variance) could not be
identified by the IOM in 1997, and, instead, an AI was
identified [118]. The AI is an estimated average intake by a
group or groups of healthy people and may not reflect the
intake needed to achieve a specific health outcome. In order
to assess whether a higher vitamin D intake resulting in
higher achieved 25(OH)D level is desirable and safe, we
performed a dose–response evaluation bringing together
data on benefits and risks of higher doses and higher
achieved 25(OH)D levels.
Based on endpoints with established causality from
double-blind RCTs as well as epidemiologic data on
cardiovascular health (incident hypertension, general mor-
tality, and cardiovascular mortality) and colorectal cancer
prevention, our review suggests that the target range of 25
(OH)D level for these benefits is not accompanied by
increased risk of hypercalcemia. Notably, all endpoints
evaluated for dose–response with higher 25(OH)D levels
point to a similar target range of at least 75 nmol/l and
better approximately 100 nmol/l.
Based on our benefit assessment, the current intake
recommendations for vitamin D using the AI are insuffi-
cient to bring a majority of individuals up to at least
75 nmol/l 25(OH)D and close to 100 nmol/l. Revising
recommendations towards a higher dose of vitamin D thus
needs an assessment of risk with vitamin D supplementa-
tion doses that may bring most of the population into the
target range of 75 to 110 nmol/l. This 25(OH)D range was
reached in most trials with 1,800 to 4,000 IU vitamin D per
day. Likely, individuals who start with lower 25(OH)D
levels will need a supplementation dose at the higher end of
this range [59, 119]. Most vulnerable to low vitamin D
levels are elderly [120, 121], individuals living in northern
latitudes with prolonged winters and thus low UVB
exposure [122, 123], obese individuals [124], and African
Americans of all ages [36, 125, 126].
In our current risk assessment, hypercalcemia was
chosen as the critical effect, the adverse effect occurring
at the lowest intake. There were no increases in mean
calcium levels with higher vitamin D intakes tested in
Fig. 3 Dose of vitamin D and achieved 25(OH)D levels based on
RCTs with a duration of at least 4 weeks. a Lower-dose trials (double-
blind fall and fracture RCTs). This graph summarizes data from
identified RCTs (as illustrated in Fig. 1) with oral doses of vitamin D
of less than 10,000 IU vitamin D per day and a treatment duration of
at least 4 weeks. Dots either represent the mean 25(OH)D level from a
single trial or the mean and the range of several trials. There were
three RCTs with 400 IU vitamin D per day with a mean increase in 25
(OH)D levels to 56.7 nmol/l (range, 44 to 64 nmol/l) after a mean
treatment duration of 653 days (range, 140 to 1148 days). The trial
with 700 IU vitamin D and achieved mean serum levels close to
100 nmol/l may be an outlier due to the high starting levels
documented in the trial (84 nmol/l in men and 72 nmol/l in women
age 65 years and older[26]). There were nine RCTs for 800 IU per day
with a mean increase in 25(OH)D levels to 75 nmol/l (range, 60 to
105 nmol/l) after a mean treatment duration of 697 days (range, 56 to
1,680 days). There were seven RCTs with 2,000 IU vitamin D per day
with a mean increase in 25(OH)D levels to 87 nmol/l (range, 71 to
103 nmol/l) after a mean treatment duration of 146 days (range, 42 to
365 days).There were three RCTs for 4,000 IU per day with a mean
increase in 25(OH)D levels to 120 nmol/l (range, 85.5 to 160 nmol/l)
after a mean treatment duration of 168 days (range, 56 to 365 days),
and there were four trials with a treatment dose between 5,720 and
7,600 IU vitamin D per day with a mean increase in 25(OH)D levels
to 128 nmol/l (range, 120–147 nmol/l). From this summary of
available dose–response data from RCTs, most trials among healthy
younger and older adults reached a mean value in the target range of
75 to 110 nmol/l with 1,800 IU to 4,000 IU vitamin D3 per day treated
for at least 42 days
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controlled trials up to 100,000 IU per day. For single cases
of hypercalcemia from RCTs, there were cases of mild
hypercalcemia from two of 28 studies, which resolved on
repeating fasting samples in one study [48] and were more
frequent in the placebo group in the second study [47].
When we extend our assessment of risk to include case
reports of hypercalcemia and associated 25(OH)D levels,
hypercalcemia occurred in 22 of 24 cases beyond
240 nmol/l 25(OH)D. Of the two cases that occurred at serum
levels below 240 nmol/l 25(OH)D, one case involved an 85-
year-old woman who reported consuming 400 IU/d vitamin D
and had a 25(OH)D of 62 nmol/l [93].The other was described
in a newly arrived adoptee with unknown vitamin D exposure
[110]. Notably, 21 of 24 cases of hypercalcemia occurred with
25(OH)D levels beyond 400 nmol/l.
The only RCT that documented an increased risk of
nephrolithiasis was the WHI, which tested 400 IU vitamin
D in combination with 1,000 mg of calcium (hazard
ratio,1.17; 95% confidence interval, 1.02 to 1.34)[24].
Whether this was the only trial large enough to detect a
small risk of nephrolithiasis with vitamin D supplementa-
tion or whether this was caused by the substantial calcium
supplement intake taken in combination with the vitamin D
and/or the additional calcium and vitamin D supplements
taken by the majority of participants outside the study
protocol in the WHI trial is unclear. However, the low-dose
vitamin D used in the WHI argues against a causal role of
the increased risk of nephrolithiasis. Based on epidemio-
logic data, a higher vitamin D intake was not independently
associated with nephrolithiasis in one large cohort [127]
consistent with findings from a recent study of 18 healthy
postmenopausal women with vitamin D deficiency where
vitamin D supplementation did not increase urinary calcium
excretion [128]. On the other hand, calcium supplementa-
tion was associated with a 20% increased risk of neph-
rolithiasis in the Nurses’ Health Study I [129], although not
in a cohort of younger women [129]. Overall, the data are
insufficient to identify nephrolithiasis as the critical effect.
The issue of vascular calcification in persons on renal
dialysis has also been addressed in detail in the 2007 risk
assessment and is not addressed in this review [22].
However, reports in the literature continue to be restricted
to extremely high doses of vitamin D3 or administration of
the active hormonal form, 1,25(OH)2D3 and/or related
analogues, and most of these reports are in animals, not
humans. There continues to be no credible evidence to
support the notion that oral vitamin D doses up to and even
exceeding 10,000 IU per day are associated with vascular
calcification in humans, including dialysis patients, and
there is no basis for identifying vascular calcification as the
critical effect.
There are several limitations to the evaluation of dose–
response relationship through a trend–plot approach using
mean serum calcium levels after treatment in trials that also
report 25(OH)D levels. This approach may miss single
cases of hypercalcemia. To address this problem, we also
assessed the report of hypercalcemia in all available
controlled trials without evidence of an increased risk with
higher achieved 25(OH)D levels up to 640 nmol/l or a daily
dose of 100,000 IU vitamin D from controlled trials. Also,
in theory, a direct comparison of the benefit and risk
resulting from consumption of vitamin D would require a
common metric. As an indicator of risk, we used increases
in mean or individual case serum calcium level (a
continuous variable, within the range permitted by physi-
ological controls), while the benefit was assessed with the
endpoints fall and fracture prevention, as well as endpoints
of cardiovascular health and colorectal cancer prevention
(categorical outcomes for individuals with population
effects identified as relative risk). General limitations to
this assessment of benefit and risk of vitamin D are that our
findings may not be generalizable to particularly vulnerable
subgroups of the population, such as patients of high age in
critical care or those with hypersensitivity to vitamin D (e.
g., sarcoidosis), as high-dose vitamin D trials are either
ongoing or have not been performed in such populations.
Also, we used the equivalent daily dose of vitamin D for
intermittent dosing of weekly or monthly applications,
which may overestimate the per day dose to some degree
[130]. However, the benefit and risk assessment from RCTs
is similar if achieved 25(OH)D levels are plotted instead of
dose. Finally, we have selected observational data on the
benefit of vitamin D, which may largely, but not fully
represent the available literature.
The IOM established a UL for vitamin D based on
hypercalcemia as the critical effect, and two studies have
been cited as a matter of concern by the IOM, (1) the trial
by Honkanen et al. included in our risk assessment and (2)
the trial by Narang et al. not included in our risk assessment
as 25(OH)D levels were not available. Notably, in the trial
by Honkanen et al. the hypercalcemia observed is not
relevant to the risk assessment of vitamin D because it
occurred in the institutionalized control group with a mean
serum 25(OH)D concentration of 10.4 nmol/l [45]. Both
groups of hospitalized and community-dwelling older
adults showed no increase in serum calcium levels with
1,800 IU vitamin D per day. The trial of Narang et al. [68]
that IOM relied upon to identify a no observed adverse
effect level of 2,400 IU vitamin D per day and establish a
UL of 2,000 IU per day is now considered unreliable
because several other more recent clinical trials included in
our risk analysis have failed to confirm the occurrence of
hypercalcemia at intakes of up to more than ten-fold those
used in that study [118]. Consequently, the 2007 risk
assessment concluded that the UL could be safely adjusted
upward to 10,000 IU [22]. Nonetheless, in general, the
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causal relationship between excessive vitamin D intake and
hypercalcemia is well-established [22] but the dose that will
result in this critical effect is higher than any used in the
RCTs and prospective cohort studies that have been
reported. Thus, the flat-line relationship of serum calcium
to the other parameters in Fig. 1a, b does not contradict the
identification of hypercalcemia as the critical effect for
excess vitamin D; it indicates only that the effect must
occur at higher 25(OH)D concentrations and with higher
oral intakes of vitamin D.
As calcium absorption is improved with higher serum 25
(OH)D levels [131, 132], future studies may need to
evaluate whether current calcium intake recommendations
with higher doses of vitamin D beyond 2,000 IU per day
are safe or require downward adjustment [131]. If dietary
calcium is a threshold nutrient, as suggested by Dr. Heaney
[119], then that threshold for optimal calcium absorption
may be at a lower calcium intake when vitamin D status is
adequate. Regarding relevant endpoints, a downward
adjustment of calcium intake recommendations is supported
by the recent meta-analysis on non-vertebral fracture
prevention where fracture prevention at a vitamin D dose
greater than 480 IU per day was independent of additional
calcium supplementation. Also, two recent epidemiologic
studies suggested that both PTH suppression [132] and hip
bone density [133] may only depend on a higher calcium
intake if serum 25-hydroxyvitamin D levels are very low.
Summary
In this analysis, we examined benefits (reductions in
fractures and falls) and risks (hypercalcemia) as a function
of vitamin D intake and serum concentrations of 25(OH)D
in randomized trials. We also used non-randomized
evidence to evaluate the levels of 25(OH)D at which
benefits (reductions in colorectal cancer and cardiovascular
disease) and risks (hypercalcemia and nephrolithiasis) are
observed. We found no pattern of evidence to suggest that
risks are elevated within the ranges of serum 25(OH)D or
oral vitamin intake related to increased benefits ( 75–
110 nmol/l). Instead, the reliable evidence that excess
vitamin D can cause hypercalcemia in generally healthy
adults comes from daily intakes of vitamin D greater than
100,000 IU or serum 25(OH)D exceeding 240 nmol/L,
which are far higher than those necessary to achieve the
benefits. The evidence from randomized trials suggests
that the dose of vitamin D supplement needed to bring
the large majority of persons to the range of optimal serum
25(OH)D may be in the range of 1,800 to 4,000 IU per
day. Further work is needed, taking into account subject
and environment factors, to better define the doses that will
achieve the optimal blood levels in the large majority of the
population.
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